Merck & Co., Inc. Disposal Group, Including Discontinued Operation, Revenue
Merck & Co., Inc. (MRK) reported Disposal Group, Including Discontinued Operation, Revenue of $2.51 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-26.
Discontinued › Income Statement › Other Income
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue · last filed 2024-02-26
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for the quarter ending 2021-06-30 was $1.06B, a 30.28% decline year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for the quarter ending 2021-03-31 was $1.45B.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for fiscal 2021 was $2.51B, a 61.21% decline from fiscal 2020.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for fiscal 2020 was $6.48B, a 16.10% decline from fiscal 2019.
- Merck & Co., Inc. disposal group, including discontinued operation, revenue for fiscal 2019 was $7.72B.
| Period end | Disposal Group, Including Discontinued Operation, Revenue 3 month | Disposal Group, Including Discontinued Operation, Revenue 6 month | Disposal Group, Including Discontinued Operation, Revenue 9 month | Disposal Group, Including Discontinued Operation, Revenue 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $1.06B derived: sum of 3 quarters · filed 2024-02-26 | $2.51B 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.06B derived: sum of 2 quarters · filed 2022-11-03 | $2.51B 10-Q · filed 2022-11-03 | $4.08B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $1.06B 10-Q · filed 2022-08-05 | $2.51B 10-Q · filed 2022-08-05 | $4.08B derived: sum of 3 quarters · filed 2023-02-24 | $5.70B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $1.45B 10-Q · filed 2022-05-05 | $3.02B derived: sum of 2 quarters · filed 2023-02-24 | $4.64B derived: sum of 3 quarters · filed 2023-02-24 | $6.16B derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $1.56B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $3.19B derived: sum of 2 quarters · filed 2023-02-24 | $4.71B derived: sum of 3 quarters · filed 2023-02-24 | $6.48B 10-K · filed 2023-02-24 |
| 2020-09-30 | $1.62B 10-Q · filed 2021-11-05 | $3.14B derived: sum of 2 quarters · filed 2021-11-05 | $4.91B 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $1.52B 10-Q · filed 2021-08-09 | $3.29B 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $7.72B 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |